Galectin Therapeutics Inc.GALT
Scheduled
Galectin Therapeutics Inc. H.C. Wainwright 28th Annual Global Investment Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- Galectin Therapeutics presented an update on their clinical development program for Valapectin, their lead compound targeting MASH thrombosis and portal hypertension as well as oncology.
- Valapectin is a potent inhibitor of galectin 3, implicated in chronic fibrotic and inflammatory conditions.
- Two Phase 2b studies in MASH thrombosis and portal hypertension showed Valapectin improved portal pressure, reduced incidence of new varices, and favorably changed multiple fibrotic biomarkers.
- A Phase 2b study in metastatic and head and neck cancer showed favorable data combining Valapectin with PD-1 inhibitors.
- Approximately 3.3 million patients in the U.S. are affected by MASH thrombosis and portal hypertension, with only about 12,000 annual liver transplants, highlighting a high unmet medical need.
- Market research suggests Valapectin could represent a multi-billion dollar opportunity once approved.
- The Navigate Phase 2b trial enrolled 357 patients treated for 18 months with 2 mg and 4 mg doses of Valapectin or placebo, assessing a composite primary endpoint including new varices development.
- In the intent-to-treat population, Valapectin 2 mg reduced incidence of new varices by 43.2% compared to placebo (10.1% vs. 17.8%), though the composite primary endpoint did not reach statistical significance.
- In the per-protocol population, the reduction in new varices was statistically significant, driven mainly by fewer large varices (8 vs. 1).
- Secondary liver complication outcomes were numerically lower with Valapectin but the trial was not powered for statistical significance on these endpoints.
- Valapectin demonstrated a strong safety profile with no drug-related serious adverse events, no drug-induced liver injury, and similar adverse event rates compared to placebo.
- Biomarker analyses showed Valapectin prevented progression of liver stiffness and fibrosis markers, with roughly 50% fewer patients worsening on Valapectin versus placebo.
- Biomarker improvements were most pronounced in sicker patients with higher baseline liver stiffness and fibrosis scores.
- Valapectin also showed favorable effects on inflammation markers such as KL40 and collagen turnover markers ProC3 and ProC4.
- The 2 mg dose consistently showed efficacy and safety across trials and is the dose planned for the Phase 3 registration trial.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring